Your session is about to expire
← Back to Search
Diagnostic Procedure
immunohistochemistry staining method for Testicular Cancer
N/A
Waitlist Available
Research Sponsored by Eastern Cooperative Oncology Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up observed at least annually
Awards & highlights
No Placebo-Only Group
Summary
RATIONALE: Diagnostic procedures may improve a doctor's ability to predict the recurrence of testicular cancer. PURPOSE: Diagnostic trial to detect the risk of recurrent disease in patients who have stage I testicular cancer and who have undergone orchiectomy within the previous 12 weeks.
Eligible Conditions
- Testicular Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ observed at least annually
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~observed at least annually
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Evidence of regional or metastatic spread
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Active Control
Group I: Laboratory/CT evaluationActive Control3 Interventions
Observation following orchiectomy
Find a Location
Who is running the clinical trial?
Eastern Cooperative Oncology GroupLead Sponsor
268 Previous Clinical Trials
151,519 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,931 Previous Clinical Trials
41,021,112 Total Patients Enrolled
5 Trials studying Testicular Cancer
65,613 Patients Enrolled for Testicular Cancer
Richard S. Foster, MDStudy ChairIndiana University Melvin and Bren Simon Cancer Center
Share this study with friends
Copy Link
Messenger